Pearl Biotech & Life Sciences Fund, L.P.
Raised
$5M
Investors
20
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
Pearl Biotech & Life Sciences Fund, L.P. is a Delaware-domiciled pooled investment fund managed by Bravance Healthcare Investors, LLC, filing under Rule 506(b) and Section 3(c)(1). This amended filing reports $4.6M raised from 20 investors; minimum investment amount is not disclosed on the filing. No parent platform has been matched in the AltStreet database.
This 506(b)/3(c)(1) pooled fund follows the standard private fund exemption pattern for healthcare-focused venture capital. With $4.6M across 20 investors, the average commitment is approximately $230K, consistent with emerging manager or niche life sciences funds targeting accredited investors through relationship-driven distribution.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
N/A Bravance Healthcare Investors, LLC
Executive Officer · McLean, VA
Lynt Johnson
Executive Officer · McLean, VA
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.